Business
Almirall 2024 Full-Year Results: Almirall Surpassed Guidance for 2024 - Entering an Era of Sustained Growth and Further Advancing Its Medical Dermatology Pipeline
BARCELONA, Spain, February 24, 2025--Almirall, S.A. (ALM):
About this update from Almirall Sa
[{"type":"image","alt":"Almirall HQ in Barcelona (Photo: Business Wire)","displaySize":"","headline":null,"caption":"Almirall HQ in Barcelona (Photo: Business Wire)","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":469,"url":"https://media.zenfs.com/en/business-wire.com/5f81ef22266744979b6fe01e7f6de124"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/dbJ3DdU6LYS7gio7f175WA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTkzODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/5f81ef22266744979b6fe01e7f6de124","width":480,"height":469}},"lazy":false},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":210,"url":"https://media.zenfs.com/en/business-wire.com/d04e7231f52b268b725ee091828e8c90"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/r3U5Gr8n0Y8mdHFV6w_IaA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQyMDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/d04e7231f52b268b725ee091828e8c90","width":480,"height":210}}},{"type":"list","items":[{"val":[{"type":"text","content":"Almirall’s net sales growth in 2024 was 10.2% YoY (total of €985.7 MM) with EBITDA growth of 10.6% YoY (total of €192.6 MM) – surpassing guidance for the year with all key growth drivers delivering double digit growth.","length":218,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Company revenue growth continues to be driven by the strong performance of the European Dermatology business (+22.5% YoY, total sales of €484.1 MM), specifically biologics.","length":172,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Ebglyss® achieved 34% growth in Q4 compared to Q3, delivering a total of €33.2 MM sales in 2024, mainly in Germany. The product is now available in 11 markets across Europe and continues to receive very positive feedback from dermatologists.","length":241,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Ilumetri® continued its very strong growth trajectory with 25.5% sales increase YoY, delivering sales of €208.8 MM – based on continued market expansion and taking a higher share from competition.","length":196,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Strong performance of Almirall´s broad dermatology portfolio: Wynzora® grew 53.3% YoY (total of €25.9 ...